Warsaw-listed medical-technology company Synektik reported EBITDA of PLN54.6mn (€12.9mn) from continuing operations in the fourth quarter of the 2024/25 financial year, a 61% y/y increase, the company said in a market filing on November 18.

Revenue in the quarter rose 41% y/y to PLN199.2mn, while net profit reached PLN30.9mn, up from PLN21mn in the third quarter of 2024.

The company said medical equipment, IT solutions and service work drove performance in August and September. That division generated PLN187.1mn in revenue, up 46% year-over-year (y/y), and PLN60.1mn in EBITDA, an increase of 68.3% year-over-year.

The radiopharmaceuticals unit reported sales of PLN12.2mn, roughly in line with the previous year. Synektik increased sales of specialised radiopharmaceuticals by 37% to a record PLN3mn, which helped offset lower sales of complementary products. EBITDA for the segment came in at PLN3.2mn, compared with PLN4.4mn a year earlier.

For the full financial year ending September 30, the group reported PLN681.3mn in revenue and PLN177.1mn in EBITDA, compared with PLN624.8mn and PLN146.3mn in the prior year.

The company said rising recurring revenue reflects growing sales of medical-therapy equipment, which boosts demand for its consumables.

Synektik said continued expansion in robotic surgery remains key to its strategic goals. In the 2024 financial year, the group sold and installed 27 da Vinci systems in hospitals in Poland, the Czech Republic and Slovakia, including nine in the final quarter. It entered the new financial year with 113 systems under its care.

The group has scope to strengthen its performance this year, helped by its broad product offering and by tender activity financed through the National Recovery Plan, vice-president Dariusz Korecki said, according to PAP.

Synektik is also working on a split that will shift its research and development in innovative radiopharmaceuticals, including a cardio-marker project, into a separate listed entity, Syn2bio. A prospectus for the planned share issue was filed with the regulator in November.